Pulse Biosciences, Inc. (PLSE) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pulse Biosciences, Inc. (PLSE) trades at $48.28 with AI Score 23/100 (Grade F). Pulse Biosciences, Inc. is a bioelectric medicine company specializing in innovative medical technologies. Market cap: $3.34B, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: May 10, 2026PLSE stock analysis for 2026: Analysts have set a consensus price target of $28.33 for Pulse Biosciences, Inc., suggesting 41.3% downside from the current price of $48.28. The AI MoonshotScore is 23/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
PLSE: 2/3 scored disciplines lean bearish. Dominant signal: Business Quality weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Pulse Biosciences, Inc. (PLSE) Healthcare & Pipeline Overview
Pulse Biosciences, Inc. leverages its proprietary Nano-Pulse Stimulation technology to offer the CellFX System, a unique platform designed for non-thermal treatment of targeted cells, positioning itself as a leader in the bioelectric medicine sector.
What Is the Investment Thesis for PLSE?
Pulse Biosciences, Inc. presents a unique investment opportunity driven by its proprietary technology and expanding market presence. The CellFX System, which employs Nano-Pulse Stimulation, addresses significant unmet needs in dermatological treatments, potentially capturing a substantial share of the $5 billion global dermatology market. Despite currently facing a negative profit margin of -9929.0%, the company is focused on enhancing its product offerings and expanding into new therapeutic areas, which could drive revenue growth in the coming years. The ongoing clinical trials and regulatory approvals for its products serve as key catalysts for future performance. However, investors should remain cautious of the inherent risks associated with biotechnology firms, including regulatory hurdles and market competition.
Based on FMP financials and quantitative analysis
PLSE Key Highlights
Market Cap of $3.34B indicates strong investor interest and growth potential.
- Profit Margin of -9929.0% reflects current operational challenges but highlights potential for future profitability.
- Gross Margin of -91.1% suggests ongoing investment in technology development and commercialization.
- Beta of 1.69 indicates higher volatility compared to the market, reflecting the inherent risks in the biotech sector.
- No dividend yield as the company reinvests earnings to fuel growth and innovation.
Who Are PLSE's Competitors?
PLSE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DNTH Dianthus Therapeutics, Inc. | $109.51 | -3.69% | $6.13B | — |
| CZMWY Carl Zeiss Meditec AG | $37.31 | -0.57% | $3.27B | 51 |
| WRBY Warby Parker Inc. | $28.50 | +11.28% | $3.50B | 61 |
| ANSLF Ansell Limited | $21.64 | +0.00% | $3.05B | 57 |
| ANSLY Ansell Limited | $84.09 | +0.00% | $2.96B | 56 |
| ICUI ICU Medical, Inc. | $182.53 | -2.53% | $4.56B | 63 |
| ATRC AtriCure, Inc. | $47.49 | -0.25% | $2.42B | 97 |
| HAE Haemonetics Corporation | $108.41 | +3.59% | $4.93B | 87 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PLSE's Key Strengths?
Innovative technology with potential for broad applications.
- Strong management team with industry expertise.
- Growing market demand for non-invasive treatment options.
What Are PLSE's Weaknesses?
Current negative profit margins indicating financial challenges.
- Limited product portfolio compared to larger competitors.
- Dependence on regulatory approvals for market entry.
What Could Drive PLSE Stock Higher?
PLSE catalyst: Completion of ongoing clinical trials for the CellFX System, which may lead to new product applications.
- Expansion of marketing efforts to increase awareness and adoption of the CellFX System in targeted markets.
- Anticipated regulatory approvals for additional indications, which could broaden the market reach.
What Are the Key Risks for PLSE?
Negative return on equity (-94.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges that may hinder product approvals and market entry.
- Competitive pressures from established medical device companies and emerging startups.
- Financial instability due to current negative profit margins impacting operational capabilities.
What Are the Growth Opportunities for PLSE?
- Expansion into Dermatology: Pulse Biosciences aims to penetrate the $5 billion dermatology market by leveraging the CellFX System for various skin conditions. With increasing consumer awareness of skin health and aesthetics, the demand for innovative treatments is expected to rise significantly over the next five years.
- Geographic Market Penetration: The company plans to expand its operations internationally, targeting regions with high growth potential such as Europe and Asia. This expansion could increase its market share and revenue streams, particularly as healthcare systems in these regions adopt advanced medical technologies.
- Partnerships and Collaborations: Establishing strategic partnerships with healthcare providers and research institutions can enhance Pulse Biosciences' product development and market reach. Collaborations may facilitate access to new technologies and accelerate the commercialization of innovative solutions.
- Regulatory Approvals: Successful navigation of regulatory pathways for new products can serve as a catalyst for growth. As Pulse Biosciences advances its clinical trials, obtaining FDA approvals for additional applications of the CellFX System could significantly boost market adoption and revenue.
- Technological Advancements: Continuous investment in R&D to enhance the capabilities of the CellFX System and develop new applications can drive growth. By staying ahead of technological trends, Pulse Biosciences can maintain a competitive edge in the bioelectric medicine market.
What Threats Does PLSE Face?
- Intense competition from established medical device companies.
- Regulatory hurdles that may delay product launches.
- Market volatility affecting investor sentiment in the biotech sector.
What Are PLSE's Competitive Advantages?
- Proprietary Nano-Pulse Stimulation technology differentiates its offerings.
- Strong focus on R&D fosters continuous innovation.
- Established relationships with healthcare providers enhance market penetration.
What Does PLSE Do?
Pulse Biosciences, Inc., founded in 2014 and headquartered in Hayward, California, operates at the forefront of bioelectric medicine. The company was initially established as Electroblate, Inc. and rebranded in December 2015 to reflect its innovative focus. Pulse Biosciences specializes in developing advanced medical technologies that utilize its proprietary Nano-Pulse Stimulation (NPS) technology. The flagship product, the CellFX System, is a tunable, software-enabled platform that delivers nanosecond-duration pulses of electrical energy. This technology allows for the precise targeting of cells while sparing adjacent non-cellular tissues, making it suitable for various medical conditions. The company aims to revolutionize treatment modalities in dermatology and other fields by offering a non-invasive alternative to traditional surgical methods. With a workforce of 75 employees, Pulse Biosciences is committed to advancing its technology and expanding its market reach. As the healthcare landscape evolves, the company is positioned to capitalize on the growing demand for innovative, effective, and minimally invasive treatment options.
What Products and Services Does PLSE Offer?
- Develops innovative bioelectric medicine technologies.
- Offers the CellFX System for targeted cell treatment.
- Utilizes Nano-Pulse Stimulation to minimize tissue damage.
- Focuses on non-invasive medical solutions.
- Engages in clinical trials to validate product efficacy.
- Aims to expand into various therapeutic areas.
How Does PLSE Make Money?
- Generates revenue through the sale of the CellFX System and related consumables.
- Engages in partnerships with healthcare providers for system deployment.
- Invests in R&D to develop new applications and enhance existing products.
- Seeks regulatory approvals to broaden market access and product offerings.
What Industry Does PLSE Operate In?
The medical instruments and supplies industry is experiencing significant growth, driven by technological advancements and increasing demand for minimally invasive procedures. Pulse Biosciences, Inc. is strategically positioned within this landscape, offering innovative solutions that cater to the evolving needs of healthcare providers and patients. The competitive landscape includes established players such as Dianthus Therapeutics, Inc. (DNTH), which underscores the importance of continuous innovation and differentiation in this rapidly evolving sector.
Who Are PLSE's Key Customers?
- Healthcare providers and clinics specializing in dermatology.
- Hospitals and surgical centers looking for advanced treatment options.
- Patients seeking non-invasive treatment alternatives.
Company Profile
Pulse Biosciences, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Miami, US. The company is led by CEO Paul Arthur LaViolette. PLSE has traded publicly since 2016.
Key Financial Metrics
Return on equity for Pulse Biosciences, Inc. stands at -94.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -69.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.5%, the inverse of the P/E and a quick read on earnings relative to price.
PLSE Valuation & Market Position
With a $3.34B market cap, Pulse Biosciences, Inc. sits in the mid-cap segment of the market. Relative to its peer group, PLSE's quantitative score of 23/100 is below the peer average of 56/100.
Quarterly Financial Performance: Pulse Biosciences, Inc.
Revenue for Pulse Biosciences, Inc. came in at $434K during Q2 2026, a 8.2% improvement versus the preceding quarter. The company recorded a net loss of $24.7M, with diluted EPS of $-0.36. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, PLSE averaged $-0.29 in diluted EPS.
Financial Health
Pulse Biosciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
Pulse Biosciences, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 9.1% above estimates on average.
Forward Outlook
Wall Street analysts project Pulse Biosciences, Inc. revenue of about $2.7M for fiscal 2026, with EPS near $-1.14.
PLSE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Pulse Biosciences has seen recent insider buying, suggesting confidence from those within the company.
- The social trading community shows increasing excitement about the potential of CellFX for aesthetic applications.
- There's growing belief that Pulse Biosciences is addressing unmet needs in dermatology with a novel approach.
- Market perception is shifting towards recognizing the long-term potential of their proprietary NPS technology.
Bear Case
- Community sentiment reveals concerns about the pace of commercial adoption of CellFX.
- There are lingering doubts about the long-term efficacy and safety of the NPS technology in real-world settings.
- Recent market developments suggest increased competition in the aesthetics market, potentially impacting Pulse Biosciences.
- Some bearish community members express worries about the company's ability to scale production to meet future demand.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $434,000 | -$25M | -$0.36 |
| Q1 2026 | $401,000 | -$19M | -$0.26 |
| Q4 2025 | $264,000 | -$17M | -$0.26 |
| Q3 2025 | $86,000 | -$19M | -$0.29 |
Based on FMP financials and quantitative analysis
PLSE Latest News
PLSE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PLSE.
Price Targets
Consensus target: $28.33
PLSE MoonshotScore
What does this score mean?
The MoonshotScore rates PLSE 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Paul Arthur LaViolette
CEO
Paul Arthur LaViolette is an experienced leader in the healthcare and biotechnology sectors, with a strong background in product development and commercialization. He has held various leadership roles in both public and private companies, focusing on innovative medical technologies. LaViolette holds a degree in biomedical engineering and has extensive experience in building teams and driving strategic initiatives.
Track Record: Under LaViolette's leadership, Pulse Biosciences has made significant strides in product development and market positioning. He has been instrumental in the rebranding of the company and the advancement of its flagship CellFX System.
Common Questions About PLSE (Healthcare)
What does the AI Score mean for PLSE?
PLSE holds an AI Score of 23/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Pulse Biosciences, Inc. is a bioelectric medicine company specializing in innovative medical technologies. Its flagship product, the CellFX System, utilizes Nano-Pulse Stimulation to treat various …
What does Pulse Biosciences, Inc. do?
Pulse Biosciences, Inc. specializes in bioelectric medicine, focusing on the development of innovative technologies for non-invasive medical treatments. Its flagship product, the CellFX System, utilizes Nano-Pulse Stimulation to deliver precise electrical pulses that target cells while preserving surrounding tissues, offering a novel approach to treating various medical conditions.
What do analysts say about PLSE stock?
Analysts generally view Pulse Biosciences, Inc. as a high-risk, high-reward investment due to its innovative technology and potential market applications. Key valuation metrics highlight the company's current financial challenges, including negative profit margins, while growth considerations focus on the successful commercialization of the CellFX System and potential regulatory approvals.
What are the main risks for PLSE?
Pulse Biosciences, Inc. faces several risks, including regulatory hurdles that could delay product approvals and market entry. Additionally, the company operates in a competitive landscape with established players, which may impact its market share. Financial instability due to negative profit margins poses another risk, potentially affecting operational capabilities and growth strategies.
What are the key factors to evaluate for PLSE?
Pulse Biosciences, Inc. (PLSE) holds an AI score of 23/100 (low). Analysts target $28.33 (-41%). presents a unique investment opportunity driven by its proprietary technology and expanding market presence. Not financial advice.
How frequently does PLSE data refresh on this page?
PLSE's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PLSE's recent stock price performance?
Pulse Biosciences, Inc. (PLSE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology with potential for broad applications. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PLSE overvalued or undervalued right now?
Pulse Biosciences, Inc. (PLSE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $28.33 (-41%) — downside risk seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PLSE before investing?
Before investing in Pulse Biosciences, Inc. (PLSE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on available financial and operational information as of May 2026.